FDA Raises Issues With Wockhardt's Key U.S. Plant, Company Says
This article was originally published in PharmAsia News
Executive Summary
Wockhardt's main production plant for the U.S. generics market is under threat in the wake of an FDA inspection that raised concerns about its production processes.